Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 14 de 14
Annals of the Rheumatic Diseases ; 81:1811-1812, 2022.
Article in English | EMBASE | ID: covidwho-2009076
Topics in Antiviral Medicine ; 30(1 SUPPL):177-178, 2022.
Article in English | EMBASE | ID: covidwho-1880620
Eur Rev Med Pharmacol Sci ; 26(5): 1777-1785, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1754188


OBJECTIVE: The first pandemic phase of COVID-19 in Italy was characterized by high in-hospital mortality ranging from 23% to 38%. During the third pandemic phase there has been an improvement in the management and treatment of COVID-19, so mortality and predictors may have changed. A prospective study was planned to identify predictors of mortality during the third pandemic phase. PATIENTS AND METHODS: From 15 December 2020 to 15 May 2021, 208 patients were hospitalized (median age: 64 years; males: 58.6%); 83% had a median of 2 (IQR,1-4) comorbidities; pneumonia was present in 89.8%. Patients were monitored remotely for respiratory function and ECG trace for 24 hours/day. Management and treatment were done following the timing and dosage recommended by international guidelines. RESULTS: 79.2% of patients necessitated O2-therapy. ARDS was present in 46.1% of patients and 45.4% received non-invasive ventilation and 11.1% required ICU treatment. 38% developed arrhythmias which were identified early by telemetry and promptly treated. The in-hospital mortality rate was 10%. At multivariate analysis independent predictors of mortality were: older age (R-R for≥70 years: 5.44), number of comorbidities ≥3 (R-R 2.72), eGFR ≤60 ml/min (RR 2.91), high d-Dimer (R-R for≥1,000 ng/ml:7.53), and low PaO2/FiO2 (R-R for <200: 3.21). CONCLUSIONS: Management and treatment adherence to recommendations, use of telemetry, and no overcrowding appear to reduce mortality. Advanced age, number of comorbidities, severe renal failure, high d-Dimer and low P/F remain predictors of poor outcome. The data help to identify current high-risk COVID-19 patients in whom management has yet to be optimized, who require the greatest therapeutic effort, and subjects in whom vaccination is mandatory.

COVID-19/mortality , Hospital Departments/organization & administration , Hospital Mortality , Internal Medicine/methods , Pandemics , Telemetry/methods , Age Factors , Aged , Critical Care , Electrocardiography , Female , Fibrin Fibrinogen Degradation Products , Humans , Italy/epidemiology , Male , Middle Aged , Oxygen/blood , Pneumonia/drug therapy , Pneumonia/etiology , Pneumonia/mortality , Predictive Value of Tests , Prospective Studies , Respiratory Distress Syndrome/drug therapy , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/mortality
Annals of the Rheumatic Diseases ; 80(SUPPL 1):907-908, 2021.
Article in English | EMBASE | ID: covidwho-1358858
Annals of the Rheumatic Diseases ; 80(SUPPL 1):1475, 2021.
Article in English | EMBASE | ID: covidwho-1358795
Eur Rev Med Pharmacol Sci ; 25(9): 3623-3631, 2021 May.
Article in English | MEDLINE | ID: covidwho-1232735


OBJECTIVE: We aimed to assess the correlation between LUS Soldati proposed score and clinical presentation, course of disease and the possible need of ventilation support/intensive care. PATIENTS AND METHODS: All consecutive patients with laboratory confirmed SARS-CoV-2 infection and hospitalized in two COVID Centers were enrolled. All patients performed blood gas analysis and lung ultrasound (LUS) at admission. The LUS acquisition was based on standard sequence of 14 peculiar anatomic landmarks with a score between 0-3 based on impairment of LUS picture. Total score was computed with their sum with a total score ranging 0 to 42, according to Soldati LUS score. We evaluated the course of hospitalization until either discharge or death, the ventilatory support and the transition in intensive care if needed. RESULTS: One hundred and fifty-six patients were included in the final analysis. Most of patients presented moderate-to-severe respiratory failure (FiO2 <20%, PaO2 <60 mmHg) and consequent recommendation to invasive mechanic ventilation (CPAP/NIV/OTI). The median ultrasound thoracic score was 28 (IQR 18-36) and most of patients could be ascertained either in a score 2 (40%) or score 3 pictures (24.4%). The bivariate correlation analysis displayed statistically significant and high positive correlations between the LUS score and the following parameters: ventilation (rho=0.481, p<0.001), lactates (rho=0.464, p<0.001), dyspnea (rho=0.398, p=0.001) mortality (rho=0.410, p=0.001). Conversely, P/F (rho= -0.663, p<0.001), pH (rho = -0.363, p=0.003) and pO2 (rho = -0.400 p=0.001) displayed significant negative correlations. CONCLUSIONS: LUS score improve the workflow and provide an optimal management both in early diagnosis and prognosis of COVID-19 related lung pathology.

COVID-19/diagnostic imaging , COVID-19/epidemiology , Hospitalization/trends , Lung/diagnostic imaging , Aged , Blood Gas Analysis/methods , Blood Gas Analysis/trends , COVID-19/therapy , Female , Humans , Italy/epidemiology , Male , Middle Aged , Prospective Studies , Ultrasonography/methods , Ultrasonography/trends